28 results on '"Slot, Annerie"'
Search Results
2. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas
3. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
4. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial
5. 2022-RA-925-ESGO Development of adjuvant treatment decision support tool for endometrial cancer patients by pooled analysis of data from 2000 women included in the PORTEC-1–3 trials and a prospective cohort study
6. 2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials
7. 2022-RA-450-ESGO Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer
8. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival
9. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data
10. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
11. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer
12. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy
13. Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
14. Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy
15. Outcome of High-Risk Stage IC, Grade 3, Compared With Stage I Endometrial Carcinoma Patients: The Postoperative Radiation Therapy in Endometrial Carcinoma Trial
16. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial
17. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients
18. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
19. Radiation Oncology in The Netherlands
20. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
21. EORTC trial 22991: Results of a phase III study comparing 6 months of androgen suppression and irradiation versus irradiation alone for localized T1b-cT2aN0M0 prostate cancer.
22. Less Gastrointestinal Toxicity After Adjuvant Radiotherapy on a Small Pelvic Field Compared to a Standard Pelvic Field in Patients With Endometrial Carcinoma
23. Target volume delineation variation in radiotherapy for early stage rectal cancer in the Netherlands
24. Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only
25. The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor
26. Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial
27. Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate Cancer
28. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.